JCR Pharmaceuticals Co., Ltd. (JP:4552) has released an update.
JCR Pharmaceuticals Co., Ltd. has regained full commercialization rights to its therapeutic product JR-141, designed to treat Hunter syndrome, after ending its collaboration with Takeda Pharmaceutical. The company has been leading JR-141’s clinical development, including the ongoing global Phase 3 clinical trials, and is planning to expand its availability beyond Japan, where it has been marketed since May 2021. The financial impact of this change on JCR’s current fiscal year is anticipated to be minimal.
For further insights into JP:4552 stock, check out TipRanks’ Stock Analysis page.
